They found that the protein was highly expressed at the tumor site, that anti-GITR therapy preferentially depleted Tregs at the tumor site, and that combining this therapy with XRT and anti-PD-1 therapy generated a systemic and durable antitumor response. Here, TNFRSF18 is linked to neoplasm.